Suda Pharmaceuticals - A TGA approval and a capital raise
SUDA has had a busy couple of months, announcing approval for ZolpiMist in Australia by the Therapeutics Goods Administration (TGA) in July, as well as raising A$4.1m in additional capital. The TGA approval demonstrates SUDA’s compliance with Good Manufacturing Practice (GMP) as well as an ability to obtain regulatory approvals. This approval will assist SUDA’s current partners in their submissions in the territories for which they are responsible.Suda Pharmaceuticals is engaged in the pharmaceutical development of drug delivery technology; and medical devices and consumables distribution. The drug delivery operation includes the ArTiMist™ project and the oro-mucosal spray drug delivery technology. Co.'s segments include: Suda, which is the pharmaceutical development segment and performs research and development to create new human pharmaceutical products by combining proven drugs with delivery technologies; Westcoast Surgical and Medical Supplies, which is the sales and logistics operation for medical devices and consumables; and Malaria Research Company, which is the pharmaceutical development segment for the treatment of malaria.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.